Literature DB >> 21960924

Emerging data in the concomitant use of immunomodulators and biologic therapies.

Gary R Lichtenstein1.   

Abstract

Year:  2008        PMID： 21960924      PMCID： PMC3096131     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

2.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

3.  Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Authors:  Murat Toruner; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; Robert Orenstein; William J Sandborn; Jean-Frederic Colombel; Laurence J Egan
Journal:  Gastroenterology       Date:  2008-01-11       Impact factor: 22.682

4.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.